Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457481 | 0.81 | DHODH (0.47) | DHODHNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL26081151 | 0.73 | DHODH (0.44) | DHODHALDH1A1 | |
| SCHEMBL23270830 | 0.72 | DEGS1 (0.55) | HCAR3NPC1RAB9ASMN1; SMN2DEGS1 | |
| SCHEMBL29078027 | 0.71 | DHODH (0.44) | DHODHMEN1KMT2A | |
| SCHEMBL15718927 | 0.69 | KDM4E (0.54) | HCAR3RAB9ASMN1; SMN2DEGS1KDM4E | |
| SCHEMBL23089212 | 0.68 | MCHR1 (0.40) | HCAR3DEGS1 | |
| SCHEMBL23089215 | 0.68 | MCHR1 (0.40) | HCAR3DEGS1 | |
| SCHEMBL11901020 | 0.67 | DHODH (0.55) | DHODHHCAR3KMT2A | |
| SCHEMBL16751973 | 0.67 | FFAR2 (0.47) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10021103 | 0.67 | DHODH (0.58) | DHODHNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| EP-4225746-A1 | MRGX2 ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | DHODH 4393/4885HCAR3 1086/4885NPC1 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.